SCHEMBL17737469

SCHEMBL17737469

CC(C)Oc1ccc(S(=O)(=O)Nc2cccc3ccncc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX12 P18054 2/20 0.56
▸ SLC40A1 Q9NP59 3/20 0.47
▸ GLO1 Q04760 2/20 0.47
▸ FFAR4 Q5NUL3 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ IDO1 P14902 1/20 0.45
▸ KMT2A Q03164 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ MAPT P10636 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ HTT P42858 2/20 0.44
▸ RORC P51449 1/20 0.44
▸ KEAP1 Q14145 3/20 0.43
▸ NFE2L2 Q16236 3/20 0.43
▸ NAMPT P43490 2/20 0.43
▸ SQSTM1 Q13501 2/20 0.43
▸ MITF O75030 1/20 0.42
▸ S1PR4 O95977 1/20 0.42
▸ S1PR1 P21453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17737455 0.91 IDO1 (0.55) ALOX12SLC40A1GLO1FFAR4RECQL
SCHEMBL17737617 0.81 RECQL (0.69) ALOX12SLC40A1GLO1RECQLIDO1
SCHEMBL17737476 0.80 ALOX12 (0.62) ALOX12SLC40A1GLO1RECQLIDO1
SCHEMBL17737677 0.79 RECQL (0.58) ALOX12SLC40A1GLO1RECQLIDO1
SCHEMBL17737442 0.77 GLO1 (0.62) SLC40A1GLO1IDO1KMT2AMEN1
SCHEMBL22536978 0.77 MAPT (0.38) ALOX12KMT2AALDH1A1MAPTLMNA
SCHEMBL17737480 0.76 FFAR4 (0.46) SLC40A1FFAR4IDO1KMT2AMEN1
SCHEMBL18889904 0.75 KMT2A (0.71) SLC40A1GLO1FFAR4KMT2AMEN1
SCHEMBL4528495 0.74 KEAP1 (0.65) GLO1HTTRORCKEAP1
SCHEMBL27705 0.73 BDKRB1 (0.50) FFAR4ALDH1A1MAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215155-B1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2020-10-14 — — EP disclosed
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase IOMET PHARMA LTD. (GB) 2019-05-14 — — US disclosed
WO-2016071283-A1 INHIBITORS OF TRYPTOPHAN-2,3-DIOXYGENASE OR INDOLEAMINE-2,3-DIOXYGENASE IOMET PHARMA LTD (GB) 2016-05-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287252-B2 Inhibitors of tryptophan-2,3-dioxygenase or indoleamine-2,3-dioxygenase TDO2, IDO2, IDO1 ALOX12 832/4885SLC40A1 2382/4885GLO1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback